US 10125131
Selective HDAC3 inhibitors
granted A61KA61K31/415A61K31/495
Quick answer
US patent 10125131 (Selective HDAC3 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regenacy Pharmaceuticals, Inc.
- Grant date
- Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K31/415, A61K31/495, A61K31/497, A61K31/5377